IL161491A0 - Tamsulosin tablets - Google Patents

Tamsulosin tablets

Info

Publication number
IL161491A0
IL161491A0 IL16149102A IL16149102A IL161491A0 IL 161491 A0 IL161491 A0 IL 161491A0 IL 16149102 A IL16149102 A IL 16149102A IL 16149102 A IL16149102 A IL 16149102A IL 161491 A0 IL161491 A0 IL 161491A0
Authority
IL
Israel
Prior art keywords
tamsulosin tablets
tamsulosin
tablets
Prior art date
Application number
IL16149102A
Other languages
English (en)
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23292437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL161491(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of IL161491A0 publication Critical patent/IL161491A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
IL16149102A 2001-11-07 2002-11-01 Tamsulosin tablets IL161491A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33105501P 2001-11-07 2001-11-07
PCT/NL2002/000695 WO2003039530A1 (en) 2001-11-07 2002-11-01 Tamsulosin tablets

Publications (1)

Publication Number Publication Date
IL161491A0 true IL161491A0 (en) 2004-09-27

Family

ID=23292437

Family Applications (4)

Application Number Title Priority Date Filing Date
IL16149102A IL161491A0 (en) 2001-11-07 2002-11-01 Tamsulosin tablets
IL16152502A IL161525A0 (en) 2001-11-07 2002-11-06 Modified release tamsulosin tablets
IL161491A IL161491A (en) 2001-11-07 2004-04-19 Tamsulosin tablets
IL161525A IL161525A (en) 2001-11-07 2004-04-20 Modified release tamsulosin tablets and unit dosage forms containing the same for the treatment of benign prostatic hyperplasia

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL16152502A IL161525A0 (en) 2001-11-07 2002-11-06 Modified release tamsulosin tablets
IL161491A IL161491A (en) 2001-11-07 2004-04-19 Tamsulosin tablets
IL161525A IL161525A (en) 2001-11-07 2004-04-20 Modified release tamsulosin tablets and unit dosage forms containing the same for the treatment of benign prostatic hyperplasia

Country Status (21)

Country Link
US (2) US20030147955A1 (zh)
EP (3) EP1443917B1 (zh)
JP (3) JP2005512997A (zh)
CN (3) CN1298317C (zh)
AT (3) ATE321544T1 (zh)
AU (1) AU2002301845B2 (zh)
CA (2) CA2465110A1 (zh)
CZ (3) CZ16809U1 (zh)
DE (4) DE20220415U1 (zh)
DK (3) DK1443917T3 (zh)
ES (2) ES2256544T3 (zh)
HU (2) HUP0401978A3 (zh)
IL (4) IL161491A0 (zh)
NL (2) NL1021822C2 (zh)
NO (2) NO340960B1 (zh)
NZ (2) NZ532589A (zh)
PT (2) PT1443917E (zh)
RU (2) RU2311903C2 (zh)
SI (2) SI1443917T1 (zh)
WO (2) WO2003039530A1 (zh)
ZA (2) ZA200403281B (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465110A1 (en) † 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
IN192381B (zh) * 2002-12-20 2004-04-10 Ranbaxy Lab
US20040253309A1 (en) * 2003-01-27 2004-12-16 Yamanouchi Pharmaceutical Co., Ltd. Enteric sustained-release fine particles of tamsulosin and its salt and manufacturing method thereof
US20060147531A1 (en) * 2003-07-01 2006-07-06 Mojca Segula Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate
KR100762846B1 (ko) * 2003-09-29 2007-10-04 씨제이 주식회사 서방성 제제
JP2007507491A (ja) * 2003-09-29 2007-03-29 シージェー コーポレーション 徐放性製剤
JP2005104914A (ja) * 2003-09-30 2005-04-21 Kyowa Yakuhin Kogyo Kk 塩基性薬剤含有製剤
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
JP2005162737A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
JP2005162736A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
AU2003286415A1 (en) * 2003-12-03 2005-06-24 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
SI21702A (en) * 2004-01-29 2005-08-31 Lek Farmacevtska Druzba Dd Preparation of amorphous form of tamsulosin
JP4603803B2 (ja) * 2004-01-30 2010-12-22 大洋薬品工業株式会社 放出制御医薬組成物およびこれを用いる製剤
PL204079B1 (pl) * 2004-08-12 2009-12-31 Inst Farmaceutyczny Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
CA2592605C (en) 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
EP1878444B1 (en) * 2005-04-28 2015-09-09 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
CN1895241B (zh) * 2005-07-12 2010-05-12 可隆制药株式会社 盐酸坦洛新的口服长效性小药丸组成物及其制造方法
WO2007017253A1 (de) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Orales präparat mit kontrollierter freisetzung eines benzolsulfonamids
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
KR20070044911A (ko) * 2005-10-26 2007-05-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
EP2026766A1 (en) * 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
EP2042169A1 (en) * 2007-09-26 2009-04-01 LEK Pharmaceuticals D.D. Controlled release tamsulosin hydrochloride tablets and a process of making them
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
CA2797809A1 (en) 2010-04-30 2011-11-03 Takeda Pharmaceutical Company Limited Enteric tablet
JP5689173B2 (ja) * 2011-05-25 2015-03-25 大鵬薬品工業株式会社 テガフール、ギメラシル、オテラシルカリウム含有有核錠
CN102579392A (zh) * 2012-03-30 2012-07-18 重庆科瑞制药(集团)有限公司 一种含有盐酸坦索罗辛的缓释制剂及其制备方法
EP3448366A1 (en) 2016-04-25 2019-03-06 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3292864A1 (en) 2017-10-12 2018-03-14 Synthon B.V. Modified release tablet composition comprising mirabegron
CA3078568A1 (en) 2017-10-12 2019-04-18 Synthon B.V. Modified release tablet composition comprising mirabegron
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3697392B1 (en) 2017-10-17 2023-11-15 Synthon B.V. Tablets comprising tamsulosin and solifenacin

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
EP0205336B1 (en) * 1985-06-11 1991-09-11 Teijin Limited Oral sustained release pharmaceutical preparation
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
JPH08502977A (ja) * 1992-11-04 1996-04-02 セプラコア，インコーポレイテッド 良性前立腺増殖およびアテローム性動脈硬化の治療法ならびに（＋）ドキサゾシン組成物
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
WO1995002419A1 (fr) * 1993-07-14 1995-01-26 Yamanouchi Pharmaceutical Co., Ltd. Remede agissant contre le dysfonctionnement urinaire associe a l'hypertrophie de la prostate
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
JPH09323926A (ja) * 1996-03-15 1997-12-16 Nikken Chem Co Ltd バルプロ酸ナトリウムの徐放性錠剤
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
US5843472A (en) * 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
JP4221068B2 (ja) * 1997-12-17 2009-02-12 興和創薬株式会社 テオフィリン徐放性錠剤及びその製造方法
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
JP2000080032A (ja) * 1998-06-26 2000-03-21 Yamanouchi Pharmaceut Co Ltd 排出障害治療剤
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
JP2000128774A (ja) * 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
CA2698347A1 (en) * 1999-05-20 2000-11-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
ID30249A (id) * 1999-08-09 2001-11-15 Yamanouchi Pharma Co Ltd Komposisi farmasi untuk terapi gejala-gejala penyakit pelaksanaan fungsi saluran air kencing bawah
JP3154710B1 (ja) * 1999-08-09 2001-04-09 山之内製薬株式会社 下部尿路症治療剤
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
EP1413294B1 (en) * 2001-07-27 2010-09-29 Astellas Pharma Inc. Composition comprising sustained-release fine particles for quick-disintegrating tablets in the buccal cavity
CA2465110A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets

Also Published As

Publication number Publication date
DE60221691D1 (de) 2007-09-20
ES2287333T5 (es) 2019-04-29
CZ16813U1 (cs) 2006-08-28
RU2335280C2 (ru) 2008-10-10
DE60210315D1 (de) 2006-05-18
NL1021822A1 (nl) 2003-05-08
ATE369128T2 (de) 2007-08-15
NO340960B1 (no) 2017-07-31
JP2005511591A (ja) 2005-04-28
JP2011051995A (ja) 2011-03-17
IL161525A (en) 2012-12-31
NL1021857C2 (nl) 2004-01-09
AU2002301845B2 (en) 2008-06-05
PT1441713E (pt) 2007-08-28
SI1441713T1 (sl) 2007-10-31
ATE321544T1 (de) 2006-04-15
DK1443917T3 (da) 2006-07-17
CZ16814U1 (cs) 2006-08-28
DE60221691T3 (de) 2019-04-04
EP1595538A3 (en) 2006-02-22
ZA200403281B (en) 2005-12-13
US20030147950A1 (en) 2003-08-07
WO2003039530A1 (en) 2003-05-15
CA2464689C (en) 2011-02-01
DE60221691T2 (de) 2008-04-30
RU2004117081A (ru) 2005-03-20
EP1443917B1 (en) 2006-03-29
CA2465110A1 (en) 2003-05-15
CA2464689A1 (en) 2003-05-15
HUP0402004A2 (hu) 2005-01-28
EP1441713A1 (en) 2004-08-04
HUP0402004A3 (en) 2008-08-28
SI1441713T2 (sl) 2019-03-29
JP2005512997A (ja) 2005-05-12
DK1441713T4 (en) 2019-02-18
NO20042374L (no) 2004-08-09
NL1021857A1 (nl) 2003-05-08
ES2287333T3 (es) 2007-12-16
CZ16809U1 (cs) 2006-08-28
DE60210315T2 (de) 2006-11-02
IL161491A (en) 2009-07-20
EP1441713B2 (en) 2018-11-14
CN102327250A (zh) 2012-01-25
NZ532592A (en) 2005-02-25
HU230830B1 (hu) 2018-07-30
DE20220415U1 (de) 2003-10-09
CN1652760A (zh) 2005-08-10
RU2004117080A (ru) 2005-04-10
NO20042375L (no) 2004-08-09
IL161525A0 (en) 2004-09-27
NZ532589A (en) 2005-02-25
PT1443917E (pt) 2006-06-30
WO2003039531A1 (en) 2003-05-15
DE20221486U1 (de) 2006-02-02
EP1441713B1 (en) 2007-08-08
RU2311903C2 (ru) 2007-12-10
HUP0401978A2 (hu) 2005-01-28
SI1443917T1 (sl) 2006-06-30
JP5536610B2 (ja) 2014-07-02
EP1595538A2 (en) 2005-11-16
AT9978U1 (de) 2008-07-15
CN1298317C (zh) 2007-02-07
US20030147955A1 (en) 2003-08-07
CN1589139A (zh) 2005-03-02
EP1443917A1 (en) 2004-08-11
HUP0401978A3 (en) 2008-07-28
ZA200403430B (en) 2006-02-22
DK1441713T3 (da) 2007-12-17
ES2256544T3 (es) 2006-07-16
NL1021822C2 (nl) 2003-07-15
DK200500297U3 (da) 2006-03-10

Similar Documents

Publication Publication Date Title
IL161491A0 (en) Tamsulosin tablets
AU2002301845A1 (en) Modified release tamsulosin tablets
EP1387679A4 (en) SULPHONAMIDES
EP1399137A4 (en) SULPHONAMIDES
DE60215145D1 (en) Sulfonamide
GB0115761D0 (en) Capsules
EP1385841A4 (en) SULPHONAMIDES
EP1385495A4 (en) SULPHONAMIDES
EP1385830A4 (en) SULPHONAMIDES
AU2002301844B2 (en) Tamsulosin tablets
AU2002341442A1 (en) Tamsulosin tablets
AU2002301844A1 (en) Tamsulosin tablets
GB2397950B (en) Diplexer
AU147578S (en) Tablet
CA92536S (en) Detergent tablet
CA92538S (en) Detergent tablet
CA92664S (en) Detergent tablet
CA92545S (en) Detergent tablet
CA92544S (en) Detergent tablet
CA92543S (en) Detergent tablet
CA92542S (en) Detergent tablet
CA92541S (en) Detergent tablet
CA92534S (en) Detergent tablet
CA92537S (en) Detergent tablet
CA92540S (en) Detergent tablet